To study the clinical efficacy and safety of the method of breaking blood and driving blood stasis in the treatment of cerebral hemorrhage at super early stage.

Eighty patients with acute cerebral hemorrhage who met the inclusion criteria in Stroke Centre of Lianjiang People’s Hospital from January 2019 to June 2020 were selected as subjects and randomly divided into observation group and control group with 40 patients in each group. The observation group was treated with western medicine plus traditional Chinese medicine (original prescription), while the control group was treated with general western medicine plus traditional Chinese medicine placebo (original prescription). Skull CT was performed once at admission, 24 h, 3 d, 7 d, and 14 d after the onset of the disease. The percentage of hematoma enlargement within 24 h after the onset of the disease, the daily change in patients’ consciousness (GCS score) during the first week, and the mortality within 14 d were recorded in each group. ELISA was used to detect the changes of inflammatory indexes before treatment, on the 3^rd day after treatment, and on the 10^th day after treatment. At the same time, improved Rankin scale (mRs), evaluation of neurological deficits (NIHSS), life ability assessment (BI index), and social function activity questionnaire (FAQ) were used to evaluate the clinical prognosis of patients in each group at the 90^th day after treatment.

There were no statistically significant differences between the observation group and the control group in the rate of hematoma enlargement, incidence of adverse reactions, and mortality within 14 d (P>0.05), the application of blood-breaking and blood-stasis removing drugs in the hyperacute stage did not significantly increase the safety risk. Compared with the control group, patients in the observation group had higher GCS scores and lower NIHSS scores on day 7 after treatment, and the difference was statistically significant (P<0.05). On the 90^th day after treatment, BI and FAQ score of patients in the observation group were higher than those in the control group, and the difference was statistically significant (P<0.05). There were no statistically significant differences in the inflammatory markers tumor necrosis factor α (TNF-α) and interleukin-1β (IL-1β) between the two groups before treatment (P>0.05), but the levels of TNF-α and IL-1β in the observation group were lower than those in the control group at the peak of edema (day 3) and after peak edema (day 10), and the differences were statistically significant (P<0.05).

The super-early treatment of cerebral hemorrhage with the method of breaking blood and driving blood stasis will not significantly increase the safety risk, which is helpful to control the inflammatory response and improve the recovery of consciousness and nerve function, and improve the clinical prognosis of patients to a certain extent.